drugset / Trial / NCT06008860

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

NCT06008860

Phase 4 Recruiting 280 enrolled University of Chicago
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.

Timeline

Start
2023-07-01
Primary completion
2026-12
Completion
2026-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelastine Small molecule 0.15 % Intranasal

Indications